CDT Equity Inc
Research CDT Equity Inc (CDT) on Bullrun: market cap USD 9.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCDT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.96M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 4.06M
- Free cash flow-USD 1.89M
Valuation Snapshot
latest market cap is USD 9.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 39.22M | -USD 17.96M | n/a | -1177.89 | USD 1.51M | USD 775.00K | -USD 7.17M |
| FY2024 | USD 0 | -USD 17.80M | -USD 9.73M | n/a | -61598.62 | USD 554.00K | USD 7.46M | -USD 6.79M |
| FY2023 | n/a | -USD 535.00K | n/a | n/a | -8.92 | USD 4.23M | USD 985.00K | -USD 457.00K |
| FY2022 | n/a | -USD 4.89M | n/a | n/a | -0.13 | USD 345.78K | n/a | -USD 10.09M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 9.96M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.95M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.35M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 273.00M | n/a | n/a | n/a |
About CDT Equity Inc
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CDT Equity Inc's market cap?
CDT Equity Inc's market capitalization is USD 9.96M.
What does CDT Equity Inc do?
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.